GlaxoSmithKline plc (GSK.L)
| Previous close | 1,397.60 |
| Open | 1,403.80 |
| Bid | 1,391.20 x 0 |
| Ask | 1,391.40 x 0 |
| Day's range | 1,389.81 - 1,405.00 |
| 52-week range | 1,190.80 - 1,548.08 |
| Volume | 2,320,575 |
| Avg. volume | 6,782,722 |
| Market cap | 70.011B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 16.03 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.80 (5.72%) |
| Ex-dividend date | 19 Aug 2021 |
| 1y target est | N/A |
- Business Wire
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps
LONDON, July 29, 2021--GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps.
- Business Wire
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra long-acting" medicines for HIV
LONDON & SAN DIEGO, Jun 22, 2021--ViiV HC and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to develop ultra-long-acting HIV medicines
- Business Wire
FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)
GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and pediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-hematologic secondary cause. The approval makes Nucala the first and only targeted biologic treatment to be approved for patients with this eosinophil-driven disease in the US.
